Ticker	Current Price	Change	Graph
IBB	105.05	0.9 (0.86%)
XBI	79.52	1.97 (2.54%)

Results

AstraZeneca’s big MYSTIC trial ends a complete failure as Imfinzi/tremelimumab combo flops on overall survival

Results

AbbVie touts promising PhIII data for Orilissa as execs line up their second pitch and rivals lay in wait

Politics, UK Biotech

While controversy over Brexit reaches full boil, a pharma trade group sees the upside in a draft deal

Latest

Pfizer preps a laundry list of drug price hikes for the New Year — let the political fireworks begin →

Sanofi teams with non-profit on a landmark new drug for sleeping sickness →

Eli Lilly partner Chi-Med sees shares tank as its newly approved cancer drug flunks PhIII lung cancer trial →

With radiotherapy en vogue, Belgian startup nabs nearly $42M in Series A funding →

Bolstered by promising PhIIb snapshot, uniQure plays catch-up with Spark in the race to a hemophilia B gene therapy →

The sandbox: Parker Institute throws its research muscle behind gene therapy tech for destroying cancer cells →

United Therapeutics pays $800M-plus to grab Arena’s PhIII PAH drug →

AbbVie enlists protein degradation experts at Mission for a new bet on Alzheimer's, Parkinson's →

Partnered with Novartis, tiny Cadent jumps out of stealth with $40M round for its CNS pipeline →

How trial innovation in Australia is getting therapies to patients sooner →

What's coming? Pazdur, Marks and Woodcock discuss FDA changes →

Can a Nektar rival make it on Nasdaq with a $100M IPO? Synthorx is giving it a shot →

FDA presses its campaign against rogue regenerative med players, cites StemGenex for illegal sales →

Eluded by clear success in esophageal carcinoma, Merck touts subgroup OS win for Keytruda →

Deerfield bankrolls an $80M research center at Dana-Farber devoted to protein degradation →

Top News

Celgene doubles down on Dragonfly's natural killer tech, expanding into solid tumors with an injection of 'amplification capital'

John Carroll

Did Novartis get $150M worth of positive PhII cardio data from Akcea?

John Carroll

South Korean regulator suspends Samsung BioLogics' stock, citing accounting violations

Endpoints Staff

New cancer target? GSK highlights oncology ambitions with its move into the clinic with RIP1 drug for pancreatic cancer

John Carroll

Kymera raises $65M from global syndicate as it aims for the clinic with protein degradation tech

John Carroll

Protocols

Quick hits from around the biopharma web

Nov 16

Takeda family preps for a last-stand vote against Shire buyout; Eli Lilly reportedly shopping drug portfolio in China

Nov 15

Centrexion delays IPO; Exelixis makes $40M as Cabometyx wins EU nod

Nov 14

Pfizer loses key Lyrica patent battle in the UK; Kleo Pharma closes $21M Series B round

Nov 13

Roche wins speedy FDA review for Tecentriq; South Korean authorities to look into Samsung BioLogics accounting practices

More Protocols

Peer Review

Weekly biopharma careers news report

Nov 16

Japanese billionaire Mikitani takes full control of Rakuten Aspyrian; HOX Therapeutics taps Karl Keegan as CEO

Nov 9

One year in, Joanne Kotz assumes CEO role at Jnana; President/Executive chair duo will now run BlackThorn

Nov 2

Sun BioPharma founder Michael Cullen steps up; SemaThera settles on permanent CEO; OncoSec nabs Kellie Malloy Foerter from Syneos

Oct 26

Longtime Apitope CEO Keith Martin steps down; Clearside Biomedical taps Spark exec as CMO

More peer review

Premium

Winners and losers at #ESMO18

Exclusive: At Hal Barron’s R&D group at GSK, consensus is out, leaders are in and watch out for an ‘intense drive’ to spur the late-stage pipeline

With its rep on the line, Celgene's newly-filed safety study spurs fresh worries over fate of ozanimod

A go-go FDA is poised to break the all-time record on new drug approvals. Is this the new standard for biopharma success?

Global reach: The top 25 biopharma companies in the world

Genentech team does some cutting-edge work on a new class of antibiotics — here's why that's important

Bioregnum

The view from John Carroll

Nov 16

Pfizer preps a laundry list of drug price hikes for the New Year — let the political fireworks begin

Nov 7

Bound to the hip with Trump, ex-Celgene chief Bob Hugin gets whipped in New Jersey Senate race

Oct 25

Fight! Trump kicks off a war of words with the drug lobby, proposing to peg Medicare prices to overseas rates

Oct 3

Sarepta shares yo-yo in the red on another glimpse of stellar results for Duchenne MD gene therapy — what gives?

More opinion

Marco

Hot BioTwitter bot - last updated ago

Most Viral

Roche withdrawal of EMA application

Europa a day

AstraZeneca provides update on the Phase III MYSTIC trial of Imfinzi and tremelimumab in Stage IV non-small cell lung cancer

AstraZeneca a day

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018

Europa a day

FDA approves first-line treatment for peripheral T-cell lymphoma under new review pilot

FDA a day

The 25 most valuable US startups that failed this year

Business Insider a day

Prospective Grant of an Exclusive Patent License: Development and Commercialization of Chimeric Antigen Receptor (CAR) Therapies for the Treatment of FMS-like tyrosine kinase 3 (FLT3) Expressing Cancers

a day

Astrazeneca drops out of one lung cancer immunotherapy race

Evaluate.com a day

Learning from failure with IO combos | Biotech Strategy Blog

Biotech Strategy Blog a day

Organisms found on hike in the woods are like no other life on Earth | CBC News

CBC a day

At 24, Two Entrepreneurs Took On Cancer. At 32, They're Worth Hundreds Of Millions

Forbes a day

Latest

MedpageToday

App Cuts Cancer Pain; Immune Tx Side Effects; Gaps in Goals of Care

Financial Times

Gene editing: careless Crispr

EurekAlert!

From the ashes of a failed pain drug, a new therapeutic path emerges

The Myeloma Crowd

Flu Season: Preparing and Protecting the Immune System When You Have Multiple Myeloma

Axios

The many reasons why drugs cost so much

The Tyee

Polio and Vaccination: A Memoir of What We've Forgotten | The Tyee

Lifescienceleader

CNS Summit 2018 Does Not Meet Expectations - It Exceeded Them

Financial Times

Pfizer to raise prices for 41 drugs despite Trump criticism

TechCrunch

SparkLabs Taipei closes initial $4.25M for its first fund, adds Jeremy Lin as an advisor

MedScape

What's Needed After AHA 2018? ACTION

Hot This Week

1

Forbes

30 Under 30 2019: Healthcare

2

Europa

Roche withdrawal of EMA application

3

STAT

Sean Parker: Health care breakthroughs aren't going to come from Google, Amazon

4

Mrknewsroom

Merck Begins Rolling Submission of Licensure Application for V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration

5

AstraZeneca

AstraZeneca provides update on the Phase III MYSTIC trial of Imfinzi and tremelimumab in Stage IV non-small cell lung cancer

6

STAT

Nebula Genomics, with free DNA sequencing, opens for business - STAT

7

STAT

Amarin, Vascepa, and mineral oil. There's more to consider with this fish-oil story

8

Europa

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018

9

Forbes

At 24, Two Entrepreneurs Took On Cancer. At 32, They're Worth Hundreds Of Millions

10

ENDPOINTS NEWS

AstraZeneca’s big MYSTIC trial ends a complete failure as Imfinzi/tremelimumab combo flops on overall survival

AbbVie touts promising PhIII data for Orilissa as execs line up their second pitch and rivals lay in wait

While controversy over Brexit reaches full boil, a pharma trade group sees the upside in a draft deal

Latest

Pfizer preps a laundry list of drug price hikes for the New Year — let the political fireworks begin →

Sanofi teams with non-profit on a landmark new drug for sleeping sickness →

Eli Lilly partner Chi-Med sees shares tank as its newly approved cancer drug flunks PhIII lung cancer trial →

With radiotherapy en vogue, Belgian startup nabs nearly $42M in Series A funding →

Bolstered by promising PhIIb snapshot, uniQure plays catch-up with Spark in the race to a hemophilia B gene therapy →

The sandbox: Parker Institute throws its research muscle behind gene therapy tech for destroying cancer cells →

United Therapeutics pays $800M-plus to grab Arena’s PhIII PAH drug →

AbbVie enlists protein degradation experts at Mission for a new bet on Alzheimer's, Parkinson's →

Partnered with Novartis, tiny Cadent jumps out of stealth with $40M round for its CNS pipeline →

How trial innovation in Australia is getting therapies to patients sooner →

What's coming? Pazdur, Marks and Woodcock discuss FDA changes →

Can a Nektar rival make it on Nasdaq with a $100M IPO? Synthorx is giving it a shot →

FDA presses its campaign against rogue regenerative med players, cites StemGenex for illegal sales →

Eluded by clear success in esophageal carcinoma, Merck touts subgroup OS win for Keytruda →

Deerfield bankrolls an $80M research center at Dana-Farber devoted to protein degradation →

Sponsored

Top News

Sponsored

Protocols

Peer Review

Premium

Winners and losers at #ESMO18

Exclusive: At Hal Barron’s R&D group at GSK, consensus is out, leaders are in and watch out for an ‘intense drive’ to spur the late-stage pipeline

With its rep on the line, Celgene's newly-filed safety study spurs fresh worries over fate of ozanimod

A go-go FDA is poised to break the all-time record on new drug approvals. Is this the new standard for biopharma success?

Global reach: The top 25 biopharma companies in the world

Genentech team does some cutting-edge work on a new class of antibiotics — here's why that's important

Bioregnum

Most Viral

Latest

Hot This Week

Contact Endpoints News

Sign in to Endpoints News

Request a magic link

Set a new password